> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BD Respiratory Viral Panel Gets Clearance
- URL: https://www.fdaweb.com/bd-respiratory-viral-panel-gets-clearance/
- Published: 2023-08-01T12:00:00.000Z
- Updated: 2026-09-14T18:47:49.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5154997

FDA has cleared a Becton, Dickinson 510(k) for the BD Respiratory Viral Panel for BD MAX System, a single molecular diagnostic combination test that BD says identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in about two hours. Previously, the test was available under an agency Emergency Use Authorization. The device uses a single nasal or nasopharyngeal swab sample to determine if a patient has Covid-19, the flu, or RSV. The company says its BD MAX molecular diagnostic platform is already in use at thousands of hospitals and medium-throughput laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period.